At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 106 enrolled
Drug / intervention
RF ablation (Rita Medical Systems Model 1500x)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Radiofrequency Ablation of Pulmonary Tumors Response Evaluation: a Prospective, Intention-to-Treat, Multicenter Clinical Trial
In Brief
A Phase 2 clinical trial evaluating RF ablation (Rita Medical Systems Model 1500x) for Non Small Cell Lung Cancer and Pulmonary Metastases. Completed, enrolled 106 participants across 7 sites in 5 countries.
Detailed Summary
The study hypothesis is that the radiofrequency (RF) ablation is a safe and effective treatment for malignant lung tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer, Pulmonary Metastases
CountriesAustralia, Germany, Italy, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2001
Primary CompletionDec 2006
Study CompletionDec 2007
First PostedJun 2008
TodayJul 2026
First PostedJun 5, 2008
Enrollment StartJul 1, 2001
Primary CompletionDec 1, 2006
Study CompletionDec 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 18.1 years ago
Interventions
RF ablation (Rita Medical Systems Model 1500x)device
computed tomography-guided RF ablation with an expandable electrode needle